Trial Profile

Radionuclide therapy using 177Lu-PSMA: extension of a pilot study in men with castrate-resistant prostate cancer to determine the clinical benefit of combination therapy with idronoxil

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Idronoxil (Primary) ; Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Acronyms LuPin; LuPIN-1

Most Recent Events

01 Feb 2023 Results (n=32) assessing response rates and efficacy using predictive tools in a sub-group of men with SPECT TTV progression published in the Journal of Nuclear Medicine
01 Jan 2023 Results of LuPin substudy published in the Journal of Nuclear Medicine
01 Apr 2022 Results published in the Journal of Nuclear Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com